Schlieren, Switzerland
NovaGo Therapeutics, founded in 2015 and headquartered in Switzerland, is a development stage biotech company pioneering advancements in human antibody therapeutics targeting spinal cord injury. With its focus within the Biotechnology and Health and Wellness sectors, the company has positioned itself at the cutting edge of medical research.
The company's core innovation lies in its fully human monoclonal antibodies designed to address central nervous system indications. These proprietary antibodies effectively block Nogo-A, a key vascular and nerve growth inhibitor, potentially transforming treatment paradigms within this field.
NovaGo's last significant financial milestone was a Fr.10.00M Series A investment dated 04 March 2019, attracting commitments from investors such as Kinled Holding Ltd, Neurimmune Holding, and Pureos Bioventures. This financial backing underscores strong investor confidence in their innovative approach and potential to redefine CNS treatments.
